Site içinde arama yapın

Aarya Jain bir ses eklendi Health
2026-03-18 06:29:45 -

Radiopharmaceuticals Market Evolution with Theranostics Applications
Polaris Market Research has introduced the latest market research report titled Radiopharmaceuticals Market Size, Share, Trends, & Industry Analysis Report By Radioisotope Type (Technetium-99, Fluorine-18), By Application, By Source, By End User, and By Region – Market Forecast, 2025–2034 that highlights the major revenue stream for the forecast period. The report...

0 Yorumlar 0 hisse senetleri 20 Views 0 önizleme

Please log in to like, share and comment!
Aarya Jain bir ses eklendi Other
2025-10-29 13:06:06 -

Sustained Innovation Enhances Theranostics Market Competitiveness
Market Overview The theranostics market size was valued at USD 2,049.68 million in 2024. The market is projected to grow from USD 2,362.26 million in 2025 to USD 8,640.97 million by 2034, exhibiting a CAGR of 15.5% during 2025–2034. Theranostics merges diagnostics and therapy to provide a patient-specific approach to treatment. This integration enables clinicians to identify disease...

0 Yorumlar 0 hisse senetleri 689 Views 0 önizleme

Please log in to like, share and comment!
Aarya Jain bir ses eklendi Health
2026-03-16 07:50:56 -

Theranostics Market Outlook Highlighting Advances in Nuclear Medicine
Polaris Market Research has introduced the latest market research report titled Theranostics Market Size, Share, Trends, Industry Analysis Report: By Product Type (Instruments, Reagents, and Software), Application, Technology, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034 that highlights...

0 Yorumlar 0 hisse senetleri 117 Views 0 önizleme

Please log in to like, share and comment!
Anuj Mrfr bir ses eklendi Health
2026-02-13 06:47:52 -

The "Neurological" Horizon: How 2026 is Using "Hot" Molecules to Treat Alzheimer's.
In late 2026, the industry is pivoting toward "Neuro-Theranostics." While oncology remains the anchor, a radical new class of "Amyloid-Clearing Radiopharmaceuticals" has entered Phase 2 trials, aiming to use targeted radiation to break down the plaques associated with Alzheimer's disease. This innovation is a primary driver for the market, as it promises to treat the brain with...

0 Yorumlar 0 hisse senetleri 266 Views 0 önizleme

Please log in to like, share and comment!